Pharmacodia Secures RMB 100 Million Series B Funding to Build a Big Data Platform for Drug R&D

VCBeat (WeChat ID: vcbeat), July 18 — Beijing Pharnex Jingwei Information Technology recently announced that it had completed a RMB 100 million-level Series B financing round in May this year. The round was led by Hanshi Investment and Yuanming Capital, with participation from existing Series A investors, including Bencao Capital and Tongxieyi Venture Capital.

Pharmadog, founded in 2013, is positioned as a “one-stop information service platform” for the biopharmaceutical industry. Under its Pharmadog Jingwei brand, it offers products such as the “Pharmadog Website,” the mobile app “Pharmadog Headlines,” WeChat official accounts, and print publications. It provides comprehensive information services and personalized customized solutions to professionals in the biopharmaceutical sector, including drug data, synthesis routes, global approvals, clinical trials, target information, and patent data.

PharmaDJ officially states that since its inception, the company has been dedicated to the research and application of big data in pharmaceuticals. It has gradually established four core business segments driven by “pharmaceutical data,” including: “Data—Global Drug R&D Information and Data Platform,” “Consulting—Professional Pharmaceutical Consulting and Investment & Financing Service Platform,” “Mall—IoT Platform for High-Quality R&D Resources,” and “PharmaDJ Headlines—Learning and Communication Platform for the Drug R&D Ecosystem.” Through these offerings, PharmaDJ provides the biomedical industry with highly valuable innovative products and professional services.

In June 2015, Yaodu completed its Series A financing round, raising tens of millions of RMB from Bencao Capital, nearly two years prior to this latest funding.

Dr. Li Jing, Chairman of Pharmadex, and Dr. Ding Hongxia, CEO, stated that following this round of financing, Pharmadex will further explore the deep integration and application of advanced IT technologies such as “big data” and “machine learning” in the pharmaceutical vertical sector, accelerate and deepen the research and development of its proprietary technologies, and continuously enhance the timeliness, precision, and forward-looking capabilities of its product portfolio. Meanwhile, the company will leverage resource advantages across the pharmaceutical industry to build a “data-driven,” internet-enabled platform covering the entire pharmaceutical industry chain.

Hanshi Investment Management Co., Ltd. was established in 2006 with the aim of providing superior asset management services to global investors. The firm specializes in various types of equity investments and large-scale cross-border mergers and acquisitions. It manages ten RMB-denominated funds and four USD-denominated funds, with assets under management exceeding RMB 30 billion. SinoRock Superior Growth Fund I, a USD-denominated fund managed by Hanshi Investment, is an equity fund focused on investing in high-growth companies. Its investment sectors include biopharmaceuticals, advanced manufacturing, and TMT-related industries.

Yuanming Capital is a cross-border investment and M&A firm specializing in the healthcare sectors of China and the United States. Leveraging substantial capital and high-level social resources, Yuanming Capital adds value to companies with the potential to become industry leaders. By integrating the advantages of domestic and international healthcare resources, capital strengths, and capital markets, the firm fully optimizes resource allocation and seeks strategic investment opportunities through robust interaction and exchange between the Chinese and U.S. healthcare and capital markets. Companies invested in by Yuanming Capital include BeiGene, Ascentage Pharma, Canaan Healthcare, and Mevion Medical Systems, among others.

Bencao Capital is a specialized fund focused on the healthcare industry, investing in multiple sectors including new drug development, medical devices, clinical diagnostics, and healthcare services. Bencao manages both RMB and USD funds, investing in domestic and overseas healthcare innovation enterprises. The next ten to twenty years will present tremendous opportunities for growth in the healthcare sector. Bencao is committed to helping cultivate a cohort of outstanding, internationally competitive healthcare companies, generating returns for investors, and establishing Bencao Capital as a successful healthcare investment brand that expands from China to the global stage.